Mecolzine (Mesalazine)

Mesalazine inhibits cyclooxygenase and lipoxygenase enzymes in the colonic lining, which reduces the production of prostaglandins and leukotrienes—key mediators of inflammation. This localized suppression of inflammatory pathways helps heal ulcerated tissue and alleviates symptoms.

The dosage of Mecolzine is determined by the prescribing clinician based on disease severity, patient weight and response. Typical rectal regimens may involve once‑ or twice‑daily administration, but the exact amount and frequency must be set by a qualified healthcare professional.

Safety data for mesalazine in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Consultation with a obstetrician or pediatrician is essential before starting therapy.

To request Mecolzine, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mecolzine is a rectal formulation, delivering mesalazine directly to the distal colon, whereas oral mesalazine tablets provide systemic exposure. Compared with sulfasalazine, mesalazine has fewer sulfa‑related side effects and a more targeted anti‑inflammatory effect, making it preferable for isolated proctitis.

Mecolzine should be stored at room temperature, below 25 °C, in its original container. Keep the product away from moisture and direct sunlight. Do not freeze. Ensure the packaging remains sealed until use to maintain product stability.

Mecolzine is supplied as a rectal preparation (enema or suppository). The patient should lie on their side, insert the dose as instructed, and retain it for the recommended time, usually several minutes, to allow optimal contact with the rectal mucosa.

Serious adverse events include severe allergic reactions (rash, swelling, anaphylaxis), significant rectal bleeding, hepatic enzyme elevation, pancreatitis, and acute kidney injury. Patients should seek immediate medical attention if they experience any of these symptoms.

Mecolzine is contraindicated in individuals with known hypersensitivity to mesalazine, 5‑ASA compounds or salicylates. It should also be avoided in patients with severe renal or hepatic impairment unless closely monitored, and in those who have experienced a severe reaction to other mesalazine formulations.